Trastuzumab (Herceptin) for early breast cancer
HAYES, Inc.
Record ID 32007000394
English
Authors' objectives:
Trastuzumab (Herceptin, Genentech Inc.) is a humanized monoclonal antibody that binds selectively to the human epidermal growth factor receptor 2 (HER2), which is expressed in large quantities on the surface of cancer cells in some types of breast tumors. Binding of trastuzumab to HER2 can slow the growth of the cancer cells and prevent spread of the tumor. Initially investigated for use in patients with metastatic breast cancer, trastuzumab is now also being studied as a neoadjuvant or adjuvant treatment for patients with early (localized) breast cancer.
Authors' methods:
Review
Details
Project Status:
Completed
Year Published:
2007
URL for published report:
http://www.hayesinc.com/hayes/crd/?crd=5668
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Breast Neoplasms
- Antibodies, Monoclonal
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
HAYES, Inc.
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.